Sovran Advisors LLC Raises Stock Holdings in Danaher Corporation $DHR

Sovran Advisors LLC raised its position in shares of Danaher Corporation (NYSE:DHR) by 1.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,759 shares of the conglomerate’s stock after buying an additional 76 shares during the quarter. Sovran Advisors LLC’s holdings in Danaher were worth $955,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp raised its position in shares of Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. Invesco Ltd. raised its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after purchasing an additional 163,332 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Robert W. Baird boosted their price target on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Evercore ISI reduced their price target on Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Barclays reiterated an “overweight” rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $246.35.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $195.26 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $200.40 and its two-hundred day moving average is $198.47. The company has a market cap of $139.82 billion, a P/E ratio of 41.55, a P/E/G ratio of 2.69 and a beta of 0.75. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.